Published in Vaccine Weekly, April 22nd, 1996
Because of this immunological profile, the antigen could be used as an adjuvant for therapeutic vaccines in which cytotoxic lymphocyte (CTL) responses are desired. This is precisely the goal of most therapeutic cancer vaccine strategies.
The antigen, dubbed LeIF, is derived from Leishmania protozoa, said Kenneth H. Grabstein, vice president of Coriza...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly